ArticleHeart (British Cardiac Society)1996
Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants.
Article in Heart (British Cardiac Society), 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Serum Liberation of Fetal Fibronectin Variants in Patients with Pulmonary Hypertension: ED-AJournal of clinical medicine · 2021Article
- Fibroblast contributions to ischemic cardiac remodeling.Cellular signalling · 2021Review
- Detection of Soluble ED-A(+) Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling.Disease markers · 2016Article
- Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.Cell adhesion & migration · 2015Review
- De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.Journal of molecular histology · 2014Article
- Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis.Histochemistry and cell biology · 2011Article
- Histochemistry and cell biology: the annual review 2010.Histochemistry and cell biology · 2011Review
- Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection.Histochemistry and cell biology · 2010Article
- Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies.Journal of molecular histology · 2010Article
- Extracellular matrix alterations in cardiomyopathy: The possible crucial role in the dilative form.Experimental and clinical cardiology · 2001Article
- Differential modes of regulation of interleukin-1beta expression by extracellular matrices.Immunology · 1999Article
- Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.Virchows Archiv : an international journal of pathology · 1996Review
- Histopathological Aspects of the Myocardium in Dilated Cardiomyopathy.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate whether disturbance of the cellular homoeostasis and integrity of cardiomyocytes in dilated cardiomyopathy (DCM) is accompanied by alterations in cell-matrix relations as indicated by changes in the deposition of fibronectin (FN) isoforms.
designTissue from a case series of patients with DCM was investigated by immunohistochemistry with antibodies against FN (all variants, clone IST4), ED-A+ FN (clone IST9), ED-B+ FN (clone BC1), and oncofetal glycosylated FN (clone 5C10). The sites of de novo synthesis of FN were demonstrated by means of non-radioactive RNA in situ hybridisation (ISH) with biotinylated FN cDNA fragments as the probe.
settingUniversity hospital. PATIENTS: Samples from 10 patients with clinical criteria and histological diagnosis of DCM and from 3 individuals with normal hearts.
interventionsSamples were obtained by right ventricular endomyocardial biopsy.
main outcome measureDistribution of oncofetal FN variants in DCM hearts.
resultsImmunostaining of FN (IST4, all variants) showed a coarse interstitial network in normal and diseased myocardium. ED-A+ FN was deposited as fine interstitial spots in normal myocardium and in DCM samples. Immunostaining for oncofetal glycosylated FN and ED-B+ FN was not seen in normal adult myocardium, whereas myocardium from DCM patients showed focal and delicate staining in the interstitium. RNA ISH showed that these deposits resulted from local FN synthesis.
conclusionThe results accord with de novo expression of oncofetal FN variants in hearts from patients with DCM. The oncofetal FN variants may serve as disease markers in myocardium affected by DCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.